KR880006206A - 퀴나졸리논 유도체 및 이의 제조방법 - Google Patents

퀴나졸리논 유도체 및 이의 제조방법 Download PDF

Info

Publication number
KR880006206A
KR880006206A KR870012999A KR870012999A KR880006206A KR 880006206 A KR880006206 A KR 880006206A KR 870012999 A KR870012999 A KR 870012999A KR 870012999 A KR870012999 A KR 870012999A KR 880006206 A KR880006206 A KR 880006206A
Authority
KR
South Korea
Prior art keywords
salt
formula
compound
halogen atom
preparation methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR870012999A
Other languages
English (en)
Korean (ko)
Inventor
요시히사 야마다
유죠 마쯔오까
Original Assignee
아다찌 게이지로
다나베 세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아다찌 게이지로, 다나베 세이야꾸 가부시끼가이샤 filed Critical 아다찌 게이지로
Publication of KR880006206A publication Critical patent/KR880006206A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
    • C07C275/48—Y being a hydrogen or a carbon atom
    • C07C275/50—Y being a hydrogen or an acyclic carbon atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR870012999A 1986-11-21 1987-11-19 퀴나졸리논 유도체 및 이의 제조방법 Ceased KR880006206A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP61-279421 1986-11-21
JP61279421A JPS63132889A (ja) 1986-11-21 1986-11-21 キナゾリノン誘導体

Publications (1)

Publication Number Publication Date
KR880006206A true KR880006206A (ko) 1988-07-22

Family

ID=17610847

Family Applications (1)

Application Number Title Priority Date Filing Date
KR870012999A Ceased KR880006206A (ko) 1986-11-21 1987-11-19 퀴나졸리논 유도체 및 이의 제조방법

Country Status (9)

Country Link
US (1) US4855298A (enExample)
EP (1) EP0269378B1 (enExample)
JP (1) JPS63132889A (enExample)
KR (1) KR880006206A (enExample)
AT (1) ATE60334T1 (enExample)
CA (1) CA1290756C (enExample)
DE (1) DE3767672D1 (enExample)
ES (1) ES2031913T3 (enExample)
GR (1) GR3001362T3 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1000821B (el) * 1988-11-22 1993-01-25 Tanabe Seiyaku Co Μεθοδος παραγωγης παραγωγων κιναζολινονης.
US5081241A (en) * 1990-10-11 1992-01-14 American Home Products Corporation Spiro-pyridazines and analogs thereof useful as aldose reductase inhibitors
TW202450B (enExample) * 1991-06-26 1993-03-21 Dainippon Pharmaceutical Co
US5814599A (en) * 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US5780050A (en) 1995-07-20 1998-07-14 Theratech, Inc. Drug delivery compositions for improved stability of steroids
US6002961A (en) * 1995-07-25 1999-12-14 Massachusetts Institute Of Technology Transdermal protein delivery using low-frequency sonophoresis
US5947921A (en) * 1995-12-18 1999-09-07 Massachusetts Institute Of Technology Chemical and physical enhancers and ultrasound for transdermal drug delivery
US6041253A (en) * 1995-12-18 2000-03-21 Massachusetts Institute Of Technology Effect of electric field and ultrasound for transdermal drug delivery
EP1563788B8 (en) 1995-08-29 2015-04-08 Nitto Denko Corporation Microporation of human skin for drug delivery and monitoring applications
JP2002515786A (ja) 1996-06-28 2002-05-28 ソントラ メディカル，エル．ピー． 経皮輸送の超音波増強
US8287483B2 (en) * 1998-01-08 2012-10-16 Echo Therapeutics, Inc. Method and apparatus for enhancement of transdermal transport
US7066884B2 (en) 1998-01-08 2006-06-27 Sontra Medical, Inc. System, method, and device for non-invasive body fluid sampling and analysis
US20060015058A1 (en) * 1998-01-08 2006-01-19 Kellogg Scott C Agents and methods for enhancement of transdermal transport
US20040171980A1 (en) * 1998-12-18 2004-09-02 Sontra Medical, Inc. Method and apparatus for enhancement of transdermal transport
US20030078499A1 (en) * 1999-08-12 2003-04-24 Eppstein Jonathan A. Microporation of tissue for delivery of bioactive agents
US8116860B2 (en) 2002-03-11 2012-02-14 Altea Therapeutics Corporation Transdermal porator and patch system and method for using same
US9918665B2 (en) 2002-03-11 2018-03-20 Nitto Denko Corporation Transdermal porator and patch system and method for using same
AU2003225735A1 (en) * 2002-03-11 2003-09-29 Altea Therapeutics Corporation Transdermal drug delivery patch system, method of making same and method of using same
US8016811B2 (en) 2003-10-24 2011-09-13 Altea Therapeutics Corporation Method for transdermal delivery of permeant substances
US20060094945A1 (en) 2004-10-28 2006-05-04 Sontra Medical Corporation System and method for analyte sampling and analysis
US7432069B2 (en) * 2005-12-05 2008-10-07 Sontra Medical Corporation Biocompatible chemically crosslinked hydrogels for glucose sensing
CA2680213C (en) 2007-03-07 2014-10-14 Echo Therapeutics, Inc. Transdermal analyte monitoring systems and methods for analyte detection
BRPI0810969A2 (pt) 2007-04-27 2015-01-27 Echo Therapeutics Inc Dispositivo de permeação da pele para a detecção de analito ou liberação transdermal de fármaco
US20110105952A1 (en) * 2009-10-30 2011-05-05 Seventh Sense Biosystems, Inc. Relatively small devices applied to the skin, modular systems, and methods of use thereof
US20110288389A9 (en) 2009-03-02 2011-11-24 Seventh Sense Biosystems, Inc. Oxygen sensor
US9295417B2 (en) 2011-04-29 2016-03-29 Seventh Sense Biosystems, Inc. Systems and methods for collecting fluid from a subject
US9033898B2 (en) 2010-06-23 2015-05-19 Seventh Sense Biosystems, Inc. Sampling devices and methods involving relatively little pain
JP6126783B2 (ja) 2009-03-02 2017-05-10 セブンス センス バイオシステムズ，インコーポレーテッド 被検体の皮膚から、および／または該皮膚の下から引き抜かれた媒体の分析用のデバイス
WO2011094573A1 (en) 2010-01-28 2011-08-04 Seventh Sense Biosystems, Inc. Monitoring or feedback systems and methods
US20120016308A1 (en) 2010-07-16 2012-01-19 Seventh Sense Biosystems, Inc. Low-pressure packaging for fluid devices
US20130158482A1 (en) 2010-07-26 2013-06-20 Seventh Sense Biosystems, Inc. Rapid delivery and/or receiving of fluids
US20120039809A1 (en) 2010-08-13 2012-02-16 Seventh Sense Biosystems, Inc. Systems and techniques for monitoring subjects
EP2637562B1 (en) 2010-11-09 2016-01-27 Seventh Sense Biosystems, Inc. Systems and interfaces for blood sampling
BR112013027351B1 (pt) 2011-04-29 2022-03-03 Seventh Sense Biosystems, Inc Dispositivo para receber fluido de um indivíduo
WO2012149126A1 (en) 2011-04-29 2012-11-01 Seventh Sense Biosystems, Inc. Plasma or serum production and removal of fluids under reduced pressure
US20130158468A1 (en) 2011-12-19 2013-06-20 Seventh Sense Biosystems, Inc. Delivering and/or receiving material with respect to a subject surface

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT321911B (de) * 1971-05-27 1975-04-25 Sandoz Ag Verfahren zur herstellung vonneuen 1-alkyl-4-phenyl-bzw.-4-(2-thienyl)6,7-methylendioxy-34-dihydro-2(1h)-chinazolinonen
JPS53653A (en) * 1976-06-23 1978-01-06 Matsushita Refrig Co Air conditioner
US4282229A (en) * 1977-02-11 1981-08-04 Pfizer Inc. Hydantoin derivatives as therapeutic agents
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
US4273775A (en) * 1979-06-13 1981-06-16 Pfizer Inc. Hydantoin derivatives, anti-diabetic compositions thereof, and method of use thereof
US4490381A (en) * 1979-11-13 1984-12-25 Imperial Chemical Industries Plc 1'-Substituted spiro[imidazolidine-4,3'-indoline]2,2',5-triones
JPS56104876A (en) * 1980-01-24 1981-08-20 Takeda Chem Ind Ltd Thiazolidine derivative
US4248882A (en) * 1980-02-12 1981-02-03 Pfizer Inc. Treating diabetes-associated complications with hydantoin amines
JPS5745185A (en) * 1980-07-21 1982-03-13 Eisai Co Ltd Hydantoin derivative and its preparation
AU566869B2 (en) * 1982-05-11 1987-11-05 Imperial Chemical Industries Plc Spiro (imidazolidine-4,3'-indoline) 2,2',5-triones
US4464380A (en) * 1983-05-25 1984-08-07 Pfizer Inc. Imidazolidinedione derivatives
US4533667A (en) * 1983-05-25 1985-08-06 Pfizer Inc. Imidazolidinedione derivatives
US4617392A (en) * 1983-09-29 1986-10-14 Ortho Pharmaceutical Corporation 4-alkyl-5,6-methylenedioxy-2-1[H]-quinazolinones useful as cardiotonic agents
JPH0660152B2 (ja) * 1985-02-09 1994-08-10 日本臓器製薬株式会社 新規オキサルル酸誘導体及び該化合物を含有する血糖低下剤
US4575507A (en) * 1985-05-29 1986-03-11 Pfizer Inc. Spiro-imidazolidines as aldose reductase inhibitors and their pharmaceutical use
US4762839A (en) * 1985-06-06 1988-08-09 Tanabe Seiyaku Co., Ltd. Quinazolinone copmpounds useful for the prophyloxis and treatment of diabetic complications

Also Published As

Publication number Publication date
JPS63132889A (ja) 1988-06-04
DE3767672D1 (de) 1991-02-28
ES2031913T3 (es) 1993-01-01
US4855298A (en) 1989-08-08
ATE60334T1 (de) 1991-02-15
EP0269378B1 (en) 1991-01-23
JPH0476994B2 (enExample) 1992-12-07
CA1290756C (en) 1991-10-15
GR3001362T3 (en) 1992-09-11
EP0269378A1 (en) 1988-06-01

Similar Documents

Publication Publication Date Title
KR880006206A (ko) 퀴나졸리논 유도체 및 이의 제조방법
KR850003890A (ko) 1H-이미다조[4,5c]-퀴놀린-4-아민의 제조방법
KR840000528A (ko) 비스-트리아졸 유도체의 제조방법
KR850000033A (ko) 8-클로로-1,5-벤조티아제핀 유도체의 제조방법
KR840007412A (ko) 벤조-헤테로 고리 화합물의 제조방법
KR880012526A (ko) l-페닐-3-나프탈레닐옥시프로판아민
KR870010078A (ko) 신규의 아미노산 유도체 및 그의 제조방법
KR880007514A (ko) 키놀린 화합물
KR890005141A (ko) 안드로스타-1,4-디엔-3,17-디온의 메틸렌 유도체의 제조방법
NZ208691A (en) Dihydrodibenzocycloheptylidene-ethylpiperazine derivatives and pharmaceutical compositions thereof
KR890007738A (ko) 파킨슨씨병 치료용 에르골린 유도체
KR850004585A (ko) 신규 아미노과니딘 유도체의 제조방법
KR890000482A (ko) (8β)-1-알킬-6-(치환된) 에르 골린의 시클로알킬아미드
KR900003177A (ko) 테트라시클릭계 우울증 치료제
KR830007631A (ko) 2-피리딘카복스아미드 유도체 및 이들의 제조방법
KR880701234A (ko) 신규 비페닐 유도체와 그의 제조 방법 및 용도
KR910014380A (ko) 이미자조피리다진 화합물, 그의 제법 및 용도
KR920007995A (ko) 벤즈아미드 유도체
KR890009901A (ko) 3-히드록시-2-(4-메톡시페닐)-5-(2-메틸아미노에틸)-2,3-디히드로-5h-1,5- 벤조티아제핀-4-온 유도체, 그의 제조 및 치료에의 이용
KR830006302A (ko) 신규 피리미딘 유도체의 제조방법
KR850000415A (ko) 퀴나졸리논 유도체의 제조방법
KR890002011A (ko) 5-할로 게노-6-아미노-니코틴산 할라이드. 이의 제조방법 및 용도
KR840001160A (ko) 벤조디옥산-이미다졸린 유도체의 제조방법
KR890002013A (ko) 치환된 피리딜알킬 케톤의 제조방법
KR920005720A (ko) 피리딘 유도체 그 제조방법 및 그 약학적 조성물

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301